Novel therapeutic agents in Waldenström's macroglobulinemia

Irene Ghobrial; Xavier Leleu; Abdel Kareem Azab; Judith Runnels; Xiaoying Jia; Hai Ngo; Molly Melhem; Feda Azab; Antonio Sacco; Phong Quang; Nicholas Burwick; Anne Sophie Moreau; Emanuel Husu; Mena Farag; Aldo Roccaro

doi:10.3816/CLM.2009.n.022

Novel therapeutic agents in Waldenström's macroglobulinemia

Irene Ghobrial, Xavier Leleu, Abdel Kareem Azab, Judith Runnels, Xiaoying Jia, Hai Ngo, Molly Melhem, Feda Azab, Antonio Sacco, Phong Quang, Nicholas Burwick, Anne Sophie Moreau, Emanuel Husu, Mena Farag, Aldo Roccaro

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

Original language	English (US)
Pages (from-to)	84-86
Number of pages	3
Journal	Clinical Lymphoma and Myeloma
Volume	9
Issue number	1
DOIs	https://doi.org/10.3816/CLM.2009.n.022
State	Published - 2009
Externally published	Yes

Bibliographical note

Funding Information:
Supported in part by the Kirsch Laboratory for WM, International Waldenstrom Macroglobulinemia Foundation, Leukemia and Lymphoma Society, and NIH R21 CA112904-01.

Keywords

Akt
Bortezomib
Everolimus
Perifosine
Waldenström

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3816/CLM.2009.n.022

Find It

Find It at U of M Libraries

Cite this

@article{a334d3e294254004abba8ce4030b9fbc,

title = "Novel therapeutic agents in Waldenstr{\"o}m's macroglobulinemia",

abstract = "Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenstr{\"o}m's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.",

keywords = "Akt, Bortezomib, Everolimus, Perifosine, Waldenstr{\"o}m",

author = "Irene Ghobrial and Xavier Leleu and Azab, {Abdel Kareem} and Judith Runnels and Xiaoying Jia and Hai Ngo and Molly Melhem and Feda Azab and Antonio Sacco and Phong Quang and Nicholas Burwick and Moreau, {Anne Sophie} and Emanuel Husu and Mena Farag and Aldo Roccaro",

note = "Funding Information: Supported in part by the Kirsch Laboratory for WM, International Waldenstrom Macroglobulinemia Foundation, Leukemia and Lymphoma Society, and NIH R21 CA112904-01.",

year = "2009",

doi = "10.3816/CLM.2009.n.022",

language = "English (US)",

volume = "9",

pages = "84--86",

journal = "Clinical Lymphoma and Myeloma",

issn = "1557-9190",

publisher = "Cancer Media Group",

number = "1",

}

TY - JOUR

T1 - Novel therapeutic agents in Waldenström's macroglobulinemia

AU - Ghobrial, Irene

AU - Leleu, Xavier

AU - Azab, Abdel Kareem

AU - Runnels, Judith

AU - Jia, Xiaoying

AU - Ngo, Hai

AU - Melhem, Molly

AU - Azab, Feda

AU - Sacco, Antonio

AU - Quang, Phong

AU - Burwick, Nicholas

AU - Moreau, Anne Sophie

AU - Husu, Emanuel

AU - Farag, Mena

AU - Roccaro, Aldo

N1 - Funding Information: Supported in part by the Kirsch Laboratory for WM, International Waldenstrom Macroglobulinemia Foundation, Leukemia and Lymphoma Society, and NIH R21 CA112904-01.

PY - 2009

Y1 - 2009

N2 - Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

AB - Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

KW - Akt

KW - Bortezomib

KW - Everolimus

KW - Perifosine

KW - Waldenström

UR - http://www.scopus.com/inward/record.url?scp=67649528659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649528659&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.022

DO - 10.3816/CLM.2009.n.022

M3 - Article

C2 - 19362982

AN - SCOPUS:67649528659

SN - 1557-9190

VL - 9

SP - 84

EP - 86

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

IS - 1

ER -

Novel therapeutic agents in Waldenström's macroglobulinemia

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this